TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps

Photos of Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma

Listen to Lalita Ramakrishnan Podcast

Summary: The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. The article is entitled “Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism.” Dr. Ramakrishnan is Professor in the Department of Microbiology, at the University of Washington. Dr. Edelstein is Director of the Clinical Microbiology Laboratory at the University of Pennsylvania. Dr. Cosma is a Research Scientist at the University of Washington. In the interview, we discuss the background of each guest interviewee, key results presented in the article, and next steps for clinical testing of compounds that inhibit efflux pumps and experiments for learning more about this mechanism for inducing drug tolerance.

Additional TB R&D News:

Critical Path Institute Announces Expansion of Regulatory Science Consortium for Tuberculosis

Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary

The arsenal to fight microbes is very weak right now

TB diagnostics: all studies recruiting patients now

Registering New Drugs for Low-Income Countries: The African Challenge

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...